Weekly Analysts’ Ratings Changes for Sutro Biopharma (STRO)

Several analysts have recently updated their ratings and price targets for Sutro Biopharma (NASDAQ: STRO):

• 12/22/2025 – Sutro Biopharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Sutro Biopharma had its price target raised by analysts at HC Wainwright to $10.00. They now have a “neutral” rating on the stock.
• 12/17/2025 – Sutro Biopharma had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
• 12/15/2025 – Sutro Biopharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Sutro Biopharma had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $100.00 price target on the stock, up previously from $20.00.
• 12/1/2025 – Sutro Biopharma had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Sutro Biopharma had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Sutro Biopharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Sutro Biopharma was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/7/2025 – Sutro Biopharma had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.

Insider Buying and Selling at Sutro Biopharma

In related news, Director Connie Matsui purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were acquired at an average price of $8.00 per share, with a total value of $40,000.00. Following the acquisition, the director owned 5,000 shares in the company, valued at approximately $40,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders purchased 11,175 shares of company stock valued at $89,598. 5.90% of the stock is currently owned by insiders.

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.